Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

54
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
54
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

78
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
78
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

70
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
70
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

263
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
263
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

60
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same author

Two-Stage Double-Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region.

Statistics in medicine·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.

Statistics in medicine·2026
Same author

Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Nov 15, 2025

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.5K

uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.

Haolun Shi1, Jiguo Cao1, Ying Yuan2

  • 1Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.

Statistics in Medicine
|March 2, 2021
PubMed
Summary

The utility-based toxicity probability interval (uTPI) design optimizes clinical trial dosing by balancing efficacy and toxicity. This novel approach simplifies dose selection for targeted agents and immunotherapies, improving patient outcomes.

Keywords:
Bayesian quasi likelihooddose desirabilitydose findingoptimal biological dosephase I/II trialsutility

More Related Videos

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.2K

Related Experiment Videos

Last Updated: Nov 15, 2025

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.5K
Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.2K

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Traditional chemotherapy dose-finding relies on maximum tolerated dose (MTD), which may not apply to molecularly targeted agents and immunotherapies.
  • Phase I/II trials integrating toxicity and efficacy can identify more clinically meaningful doses than toxicity-based Phase I trials.
  • Current methods for dose optimization in early-phase trials can be complex and may not fully capture the risk-benefit tradeoff.

Purpose of the Study:

  • To introduce a novel utility-based toxicity probability interval (uTPI) design for optimizing biological dose selection in clinical trials.
  • To provide a simplified and robust method for identifying optimal doses that balance toxicity and efficacy for novel therapeutics.
  • To develop a design that avoids parametric assumptions about dose-response relationships and directly models dose desirability.

Main Methods:

  • The utility-based toxicity probability interval (uTPI) design uses a numerical utility to summarize bivariate toxicity and efficacy outcomes.
  • It employs a quasi-binomial likelihood to model dose desirability without parametric dose-response assumptions.
  • Dose escalation/de-escalation decisions are adaptive, based on posterior desirability distributions and screening of overly toxic doses using toxicity probability intervals.

Main Results:

  • The uTPI design demonstrates desirable and robust performance across various simulation scenarios.
  • It offers a flexible framework accommodating diverse dose desirability formulations with minimal design parameters.
  • The design provides a clear decision structure, enabling pre-calculation of a dose-assignment table for simplified trial implementation.

Conclusions:

  • The proposed uTPI design offers a strengthened and simplified approach to phase I/II clinical trial dose finding.
  • It effectively identifies optimal biological doses by integrating efficacy and toxicity, crucial for targeted agents and immunotherapies.
  • The uTPI design enhances the practical implementation of clinical trials by providing a clear, adaptive decision-making process.